NASDAQ:ONCR - Oncorus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.67
  • Forecasted Upside: 653.62 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.15
▼ -0.1 (-8.00%)

This chart shows the closing price for ONCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncorus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCR

Analyst Price Target is $8.67
▲ +653.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Oncorus in the last 3 months. The average price target is $8.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 653.62% upside from the last price of $1.15.

This chart shows the closing price for ONCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Oncorus.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2022Piper SandlerLower Price TargetOverweight$40.00 ➝ $12.00Medium
3/28/2022HC WainwrightInitiated CoverageBuy$7.00High
3/10/2022Maxim GroupLower Price Target$20.00 ➝ $7.00High
3/16/2021Maxim GroupInitiated CoverageBuy$35.00Medium
10/27/2020Evercore ISIInitiated CoverageOutperform$35.00High
10/27/2020Jefferies Financial GroupInitiated CoverageBuy$22.00High
10/27/2020Piper SandlerInitiated CoverageOverweight$40.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/28/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/27/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Oncorus logo
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.15
Low: $1.13
High: $1.28

50 Day Range

MA: $1.44
Low: $1.04
High: $1.86

52 Week Range

Now: $1.15
Low: $1.03
High: $17.79

Volume

45,084 shs

Average Volume

122,624 shs

Market Capitalization

$29.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncorus?

The following Wall Street research analysts have issued stock ratings on Oncorus in the last twelve months: HC Wainwright, Maxim Group, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for ONCR.

What is the current price target for Oncorus?

0 Wall Street analysts have set twelve-month price targets for Oncorus in the last year. Their average twelve-month price target is $8.67, suggesting a possible upside of 653.6%.
View the latest price targets for ONCR.

What is the current consensus analyst rating for Oncorus?

Oncorus currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ONCR will outperform the market and that investors should add to their positions of Oncorus.
View the latest ratings for ONCR.

How do I contact Oncorus' investor relations team?

The company's listed phone number is 857-320-6400 and its investor relations email address is [email protected] The official website for Oncorus is www.oncorus.com. Learn More about contacing Oncorus investor relations.